Kidney Int October 2021 PMID 34556256

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

Download social card

Mentions

328

Peak: 43 in Oct 2023

across 5 sources since Sep 2021

Extended reach

1,003,623

potential audience

Total likes

787

Video views

24,555

Mentions per month

Sep 2021 – Jan 2025

Where it's discussed

X / Twitter216 posts
News96 articles
YouTube8 videos
Facebook4 posts
Blogs4 articles

AI synopsis

What people are saying

There is a noticeable focus on new recommendations such as personalized treatments, the use of the Oxford score, and specific management strategies for diseases like IgA nephropathy and FSGS, with language indicating enthusiasm and a desire to implement these guidelines—words like 'important,' 'support,' and mentions of webinars highlight both interest and recognition of the guidelines' significance.

AgreementModerate agreement

Most discussions acknowledge the KDIGO 2021 guidelines as an important update, showing general support for their recommendations.

InterestHigh interest

The discussions indicate high interest, with many posts sharing summaries of new practices and referencing expert webinars and conferences.

EngagementModerate engagement

Posts involve detailed references to specific sections and tools within the guidelines, suggesting a moderate level of engagement and analytical consideration.

ImpactModerate impact

The discussions reflect recognition of the guidelines’ influence on clinical practice and ongoing research in glomerular diseases.

Abstract in brief

The KDIGO 2021 guideline offers updated recommendations for diagnosing and treating glomerular diseases, which are conditions affecting the tiny filters in the kidneys.
It emphasizes personalized treatment plans based on the specific type and cause of the glomerular disease, including the use of immunosuppressive therapies and managing complications like proteinuria and hypertension.
The guideline also highlights the importance of monitoring disease progression and treatment response, advocating for a multidisciplinary approach to improve patient outcomes.]

Read the full abstract

All mentions

Updated Treatments for ANCA-Associated Vasculitis in 2023 by Prof. Dr. Alexandre Karras

Professor Alexandre Karras discusses major changes in the treatment of ANCA-associated Vasculitis since the 2021 KDIGO guidelines, reflecting recent updates and research findings to improve patient outcomes.

MARKUS at HOMe · Jul 21, 2023 5,526 views

Kidney Biopsy Techniques and Glomerular Disease Management Advances

Prof Dr Kerstin Amann discusses histological findings from nephrological patients and recent updates in diagnosing and treating glomerular diseases, emphasizing personalized approaches, immunosuppressive therapies, and…

MARKUS at HOMe · Oct 28, 2022 4,983 views

Innovative Treatments for IgA Nephropathy Explained

In this video, Prof. Dr. Jürgen Floege discusses established and innovative therapies for IgA nephropathy. Recent clinical trials reveal promising results for treatments like methylprednisolone, showing significant…

MARKUS at HOMe · Feb 16, 2024 4,121 views

Membranous Nephropathy: Diagnosis and Treatment Insights

Dr. Fernando C. Fervenza and Dr. Sanjeev Sethi discuss the pathogenesis, diagnosis, and treatment of Membranous Nephropathy. Both experts have contributed to major clinical guidelines and publications, offering a…

MARKUS at HOMe · Feb 9, 2024 3,177 views

Nephrology Insights 2022: New Treatments for Chronic Kidney Disease

Professor Marcus Säemann and colleagues discuss four emerging substances that will transform treatment strategies for patients with diabetic kidney disease, lupus, and ANCA-associated vasculitis. Finerenone, a notable…

MARKUS at HOMe · Jan 14, 2022 2,478 views

Understanding Focal Segmental Glomerulosclerosis Diagnosis and Treatment

Dr Ladan Zand discusses challenges in diagnosing and managing FSGS, emphasizing personalized treatment strategies, recent research, and the importance of monitoring disease progression in glomerular diseases.

MARKUS at HOMe · Aug 25, 2023 2,415 views

Kidney Biopsies and Glomerular Disease Management Insights

Prof Dr Kerstin Amann presents histological findings from five patients with acute or chronic kidney conditions, highlighting current approaches in diagnosing and managing glomerular diseases in line with KDIGO 2021…

MARKUS at HOMe · Oct 6, 2023 1,254 views

Impact of Rare Kidney Diseases on Kidney Failure Assessment

Dr. Daniel Gale emphasizes the critical role of rare kidney diseases in nephrology, highlighting data from the UK National Registry of Rare Kidney Diseases. This information underscores the urgency for early risk…

MARKUS at HOMe · May 10, 2024 602 views

Deutsche Gesellschaft für Nephrologie (DGfN) e.V.

@dgfn_ev · X

RT @MarkusAtHome: TOP 8: RaDaR by Drs. by Wong, Gale et al. https://t.co/OJOo35M6Md Compared to the general CKD population, patients with…

Jan 8, 2025 · 2 shares · 657 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

RT @MarkusAtHome: TOP 8: RaDaR by Drs. by Wong, Gale et al. https://t.co/OJOo35M6Md Compared to the general CKD population, patients with…

Jan 8, 2025 · 2 shares · 2,330 followers View post →

markusathome

@MarkusAtHome · X

TOP 8: RaDaR by Drs. by Wong, Gale et al. https://t.co/OJOo35M6Md Compared to the general CKD population, patients with rare kidney diseases have a higher kidney failure risk. Watch our webinar with Prof. Gale! https://t.co/EsztAmOOOl https://t.co/m2IaCtVKdT

Jan 8, 2025 · 4 likes · 2 shares · 108 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

@SethiRenalPath @JohannMorelle https://t.co/0M168rQSSb

Oct 13, 2024 · 6 likes · 2,330 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

@NephJC @brian_rifkin More on RADAR? https://t.co/i18497kTcu

Jul 10, 2024 · 1 like · 2,330 followers View post →

Nephrology Journal Club

@NephJC · X

@hswapnil Hope this image explains better than words #NephJC The source: @DannyGale_1 @gunnar_heine @AKronbichler @markusathome https://t.co/pf0N47HLEK https://t.co/nvW0M2rkHh

Jul 9, 2024 · 4 likes · 1 share · 38,197 followers View post →

Alex Willcockson, PhD

@WillcocksonR · X

RT @AKronbichler: @NephJC @kdjhaveri @RenalRadar @DannyGale_1 @IgAN_JBarratt @DrDKavanagh @KateBramham @lancet @brian_rifkin @NephroSeeker…

Jul 9, 2024 · 3 shares · 783 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

RT @AKronbichler: @NephJC @kdjhaveri @RenalRadar @DannyGale_1 @IgAN_JBarratt @DrDKavanagh @KateBramham @lancet @brian_rifkin @NephroSeeker…

Jul 9, 2024 · 3 shares · 2,330 followers View post →

Andreas Kronbichler

@AKronbichler · X

@NephJC @kdjhaveri @RenalRadar @DannyGale_1 @IgAN_JBarratt @DrDKavanagh @KateBramham @lancet @brian_rifkin @NephroSeeker @divyaa24 @priti899 @jmteakell @SayaliBThakare @beldelunesv @AnnaGaddy We had @DannyGale_1 recently at Markus@Home https://t.co/K0259cLwzB if people want to learn more about this paper pre @NephJC @gunnar_heine

Jul 9, 2024 · 11 likes · 3 shares · 2,454 followers View post →

SFNDT

@com_SFNDT · X

RT @gunnar_heine: Tonight 6:30 PM Greenwich mean time (and later on demand) "Wahres für Rares" Effects of rare diseases on kidney failure -…

May 13, 2024 · 1 share · 2,638 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

Tonight 6:30 PM Greenwich mean time (and later on demand) "Wahres für Rares" Effects of rare diseases on kidney failure - RaDaR with @DannyGale_1 @AKronbichler @AntMarlies Academic partners @dgfn_ev @com_SFNDT @oegnephro https://t.co/vXV5u3gqdM via @YouTube

May 10, 2024 · 4 likes · 1 share · 2,330 followers View post →

Alina

@gesof1986 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Apr 12, 2024 · 14 shares · 119 followers View post →

Estelle

@fikrysagara · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Apr 12, 2024 · 14 shares · 135 followers View post →

Serendip

@serendip3134 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 20, 2024 · 22 shares · 1,375 followers View post →

Noroژa

@n0r0zha · X

Regarding Membranous Nephropathy https://t.co/DUQIlki8mQ

Feb 20, 2024 · 2 likes · 8,349 followers View post →

Hilda Villafuerte Ledesma

@HildaVillafuer2 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 18, 2024 · 14 shares · 64 followers View post →

Guadalupe Hernandez

@mghbrr · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 18, 2024 · 22 shares · 216 followers View post →

fernando fervenza

@fervenzafernan1 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 17, 2024 · 14 shares · 4,115 followers View post →

Mohamed E. Elrggal

@M_Elraggal · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 17, 2024 · 22 shares · 1,699 followers View post →

DGG

@DGG7334 · X

RT @gunnar_heine: IgA Nephropathie - Prof. Dr. Jürgen Floege (Aachen) mit @AKronbichler Dr Gauckler @oegnephro @com_SFNDT @dgfn https://t…

Feb 17, 2024 · 2 shares · 112 followers View post →

Alok Sharma

@draalok · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 17, 2024 · 22 shares · 1,471 followers View post →

Lyzinhawer Alza

@LyzinhawerA · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 17, 2024 · 22 shares · 22 followers View post →

Bhavya dasara

@bhavya_dasara · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 17, 2024 · 22 shares · 786 followers View post →

Nikhilb

@Nikhilb5887 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 17, 2024 · 22 shares · 442 followers View post →

NephroLOGY BOX. GUO's

@ulusalokyay · X

RT @gunnar_heine: IgA Nephropathie - Prof. Dr. Jürgen Floege (Aachen) mit @AKronbichler Dr Gauckler @oegnephro @com_SFNDT @dgfn https://t…

Feb 16, 2024 · 2 shares · 167 followers View post →

David Rosenthal

@adobefalls · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 236 followers View post →

Sandra Herrmann MD, FASN

@HerrmannMd · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 2,218 followers View post →

Wisit Cheungpasitporn MD FACP | FASN | FAST

@wisit661 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 2,734 followers View post →

fernando fervenza

@fervenzafernan1 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 4,115 followers View post →

NephroLOGY BOX. GUO's

@ulusalokyay · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 167 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

IgA Nephropathie - Prof. Dr. Jürgen Floege (Aachen) mit @AKronbichler Dr Gauckler @oegnephro @com_SFNDT @dgfn https://t.co/7rume6w3Z1 via @YouTube

Feb 16, 2024 · 8 likes · 2 shares · 2,330 followers View post →

Victor Lopez Baez MD, MSc

@va_lopezb · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 574 followers View post →

Nephro

@Nephro18 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 827 followers View post →

Abhishek

@aksrulz13 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 622 followers View post →

rmohty

@rmohty · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 608 followers View post →

manuel macia heras

@mmacia25 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 806 followers View post →

Jose De La Flor

@josedelaflor4 · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 455 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 2,330 followers View post →

Hans-Joachim Anders

@hjanders_hans · X

RT @NDTsocial: MARKUS @ HOMe NDT paper of the month! Fernando Fervenza and Sanjeev Sethi explain pathogenesis, diagnosis, and treatment of…

Feb 16, 2024 · 22 shares · 2,937 followers View post →

NDT

@NDTsocial · X

Feb 16, 2024 · 54 likes · 22 shares · 18,107 followers View post →

Nephro

@Nephro18 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 11, 2024 · 14 shares · 827 followers View post →

Ayoub Mebarki

@AyoubMeb · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 10, 2024 · 14 shares · 42 followers View post →

Adil Rashid MD

@adil_rashidk · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 10, 2024 · 14 shares · 1,450 followers View post →

Silence

@XingChen381191 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 9, 2024 · 14 shares · 7 followers View post →

Sanjeev Sethi

@SethiRenalPath · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 9, 2024 · 14 shares · 13,955 followers View post →

Hans-Joachim Anders

@hjanders_hans · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 9, 2024 · 14 shares · 2,937 followers View post →

Orchidee

@Orchide11848413 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 9, 2024 · 14 shares · 573 followers View post →

Abdelhamid Hamdy

@abdelhamed012 · X

RT @gunnar_heine: Here comes MARKUS at HOMe's first 2024 @NDTsocial Special @AKronbichler & I are honored to host tonight (the) 2 world le…

Feb 9, 2024 · 14 shares · 3,299 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

Feb 9, 2024 · 29 likes · 14 shares · 2,330 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

@AKronbichler @fervenzafernan1 @SethiRenalPath https://t.co/36c0tCTwrn

Dec 20, 2023 · 2 likes · 2,330 followers View post →

Jason Diep

@DrJasonDiep · X

KDIGO 2021 Guidelines have a separate section on how to treat SLE patients with TMAs. It could be thrombotic thrombocytopenic purpura (TTP), complement-TMA, or anti-phospholipid syndrome (APLS). Each needs a different approach! DOI: 10.1016/j.kint.2021.05.021 https://t.co/LQTQQfiLJ2

Nov 21, 2023 · 1 like · 17 followers View post →

JOON T

@TubuloToxic · X

RT @ckd_ce: 3) IgA #nephropathy (#IgAN) is the most common pattern of primary #glomerular disease worldwide and remains a leading cause of…

Oct 12, 2023 · 1 share · 1,028 followers View post →

soda_troubles,https://med-mastodon.com/@haysam

@set_fortess · X

RT @ckd_ce: 36) It may be reasonable to delay initiation of #ACEi or #ARB in pts w/o #hypertension who have #podocytopathy(Minimal Change D…

Oct 12, 2023 · 1 share · 2,541 followers View post →

@CKD_ce

@ckd_ce · X

57) The correct answer per the 2021 @goKDIGO #IgAN #guidelines is b, >0.75-1 g/day. Further, #proteinuria reduction to under 1 g/d is a surrogate marker of improved #kidney outcome in #IgAN. https://t.co/4jLrZvGyMK

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

51) #Contraception is also an important consideration. #ACEi and #ARB and many #GN therapies are known to be Category X (potentially #teratogenic or #embryotoxic) medications. https://t.co/4jLrZvGyMK https://t.co/6E23y17Etn

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

50b) A review of women diagnosed with #GN showed that many patients presented during #pregnancy with complications, and this may be an opportunity for healthcare providers to act early in the disease process. https://t.co/4jLrZvGyMK https://t.co/bhYQfLk0ND

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

49d) ... and should be deferred until prednisone dose is <20 mg/day and/or immunosuppressive agents have been stopped for at least 1–3 months https://t.co/4jLrZvGyMK https://t.co/VEzAXnJTeV

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

48) Patients with elevated serum #cholesterol who are at risk for #CV complications should follow a

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

47) Calorie restriction in pts w/⬇️ GFR & #BMI > ideal is rec'd to facilitate wgt loss & prevent #CV & #kidney complications (i.e., faster rate of progression of CKD and kidney failure). Pts w/ #GFR <60 ml/min per 1.73 m2 should consume 30–35 kcal/kg/day https://t.co/4jLrZvGyMK https://t.co/1391P2QZLj

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

46) Ensure adequate dietary #protein intake in the patient with #proteinuria(0.8–1.0 g/kg daily), with a high #carbohydrate intake (35 kcal/kg ideal body weight, unless #obese) to maximize utilization of that protein. https://t.co/4jLrZvGyMK https://t.co/f6kq504af7

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

44c) Extremely limited data are available regarding the efficacy of #ezetimibe or #fibrates for lowering low-density lipoprotein (#LDL) in NS https://t.co/4jLrZvGyMK Artwork by @medcomic https://t.co/WP3Zxw78eE

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

45) As previously mentioned, dietary restriction of Na to < 2.0 g/day (<90 mmol/day) is a primary tenet for control of BP & edema (especially in the nephrotic patient) & to improve urinary protein excretion independently of meds that ⬇️proteinuria https://t.co/4jLrZvGyMK https://t.co/H8RVbsA4WS

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

43c) Tx of #hyperlipidemia in pts with NS may follow the guidelines for general population, tho demonstration of #CV event ⬇️ or #QoL ⬆️ is lacking in patients with hyperlipidemia from glomerular dz or its tx. https://t.co/4jLrZvGyMK https://t.co/MHf7tafdDk

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

42) Advise pts to restrict dietary Na to < 2.0 g/day (<90 mmol/day), normalize weight, exercise regularly & stop

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

40) Use K+ lowering agents in patients who develop #hyperkalemia. These include diuretics, #patiromer, #sodium_zirconium_cyclosilicate https://t.co/4jLrZvGyMK

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

39) Titration of #ACEi or #ARB may cause AKI and/ or hyperkalemia.

Oct 11, 2023 · 2 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

37) #Proteinuria reduction to under 1 g/d is a surrogate marker of improved #kidney outcome in #IgAN, and is a reasonable treatment target https://t.co/4jLrZvGyMK https://t.co/gu1strqArk

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

36) It may be reasonable to delay initiation of #ACEi or #ARB in pts w/o #hypertension who have #podocytopathy(Minimal Change Disease #MCD, Steroid Sensitive Nephrotic Syndrome, or Primary #FSGS). Proteinuria goal is disease specific in adult pts w/ GN https://t.co/4jLrZvGyMK https://t.co/841lESus03

Oct 11, 2023 · 1 like · 1 share · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

35) Uptitrating the dose is indicated in those with persistent #proteinuria despite treatment of the primary #GN with #immunosuppression (where indicated) Avoid the use of an #ACEi or #ARB if the

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

33c) Do not stop #ACEi or #ARB for modest & stable increase in serum creatinine (up to 30%) Stop

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

33b) There is little evidence to suggest that ACEi differ from ARBs in this respect. The combination may add some antiproteinuric activity, but has been associated w/ ⬆️in AKI & hyperkalemia events in RCTs of diabetic subjects https://t.co/4jLrZvGyMK https://t.co/jJFPluioWB

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

31b) Lifestyle modification (salt restriction, weight normalization, regular exercise, reduction in alcohol intake, and smoking cessation) should be an integral part of the therapy for BP control https://t.co/4jLrZvGyMK https://t.co/FeBAaDX8D1

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

32a) Reduction in #proteinuria is important, as it reflects control of the primary disease, reduction of glomerular hypertension, and also reduction of #podocyte damage (likely a major factor in glomerular scarring). https://t.co/4jLrZvGyMK https://t.co/s3y7xZuu6i

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

30b) Combining a loop diuretic with a #thiazide-like #diuretic (hydrochlorothiazide, metolazone, chlorthalidone) can be an effective oral regimen to overcome diuretic resistance, by blocking sodium resorption at several sites within the #nephron https://t.co/4jLrZvGyMK https://t.co/GCe40BU6vg

Oct 11, 2023 · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

29) The mainstays of tx are diuretics + moderate dietary Na restriction (1.5–2 g/d or 60–90 mmol/d). Nephrotic pts often #diuretic resistant, even if GFR is normal. Loop diuretics are first-line in tx'ing nephrotic edema; BID usually preferred https://t.co/4jLrZvGyMK https://t.co/btEXway8es

Oct 11, 2023 · 2 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

28) Significant edema & weight gain are common with nephrotic syndrome. This clinical presentation can complicate a patient’s symptoms and control of BP and may be mediated by an intrinsic defect in sodium excretion by the kidney. https://t.co/4jLrZvGyMK https://t.co/3ivxXlW4Jm

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

27) Here is a summary of supportive management of #glomerular diseases in general (not just #IgAN) https://t.co/4jLrZvGyMK https://t.co/UokTKmLBWp

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

26) Keeping with our charge of addressing “The Role of Primary Care Physicians and Advanced Practice Providers in the Diagnosis, Referral, and Management of Patients with Immunoglobin A Nephropathy,” let us now focus on supportive treatment. https://t.co/4jLrZvGyMK https://t.co/aQO94P0QXR

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

25b) Variant forms of #IgAN: IgA deposition with minimal change disease (#MCD), IgAN with acute kidney injury (#AKI), and IgAN with rapidly progressive glomerulonephritis (#RPGN) may require specific immediate treatment https://t.co/4jLrZvGyMK https://t.co/xpLl1w4p4l

Oct 11, 2023 · 1 like · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

24) The #PCP should assess #cardiovascularrisk and commence appropriate interventions as necessary, as per https://t.co/4jLrZvGyMK https://t.co/rVeZwnO80N

Oct 11, 2023 · 1 like · 2,636 followers View post →

Abdelhamid Aboghanem

@AbdelhamidAbog5 · X

RT @ckd_ce: 17) Importantly, MEST-C score was developed to predict

Oct 10, 2023 · 1 share · 19 followers View post →

soda_troubles,https://med-mastodon.com/@haysam

@set_fortess · X

RT @ckd_ce: 6b) #IgAN is relatively rare in individuals of African descent. It is unclear if these observations are due to differences in p…

Oct 10, 2023 · 1 share · 2,541 followers View post →

@CKD_ce

@ckd_ce · X

20) Important limitation: It is particularly important to emphasize that one cannot use the tool to make inferences about treatment. However, one can envision using the tool for clinical trial design and analysis in the future https://t.co/4jLrZvGyMK https://t.co/bAKpETeCwV

Oct 10, 2023 · 3 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

19a) Using clinical & histologic data at biopsy, users can determine a 50% ⬇️ in eGFR or kidney failure at selected time intervals. Note that te tool is not validated for use with data obtained remotely from the time of biopsy https://t.co/4jLrZvGyMK

Oct 10, 2023 · 3 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

18b) The International #IgAN Prediction Tool quantifies risk of progression & ands inform shared decision-making with pts. It incorporates clinical info at the time of #biopsy & cannot be used to determine the likely impact of any particular tx regimen. https://t.co/4jLrZvGyMK https://t.co/RPrNcb9LcQ

Oct 10, 2023 · 4 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

17) Importantly, MEST-C score was developed to predict

Oct 10, 2023 · 3 likes · 1 share · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

14) See Practice Point 2.1.1: Considerations for the diagnosis of #IgAN: - IgAN can only be diagnosed with a kidney biopsy. - There are no validated diagnostic serum or urine biomarkers for IgAN. - Assess all patients with IgAN for secondary causes https://t.co/4jLrZvGyMK https://t.co/tAnNXPj1PW

Oct 10, 2023 · 4 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

15) #PCPs should determine the #MEST_C score (mesangial [M] & endocapillary [E] hypercellularity, segmental sclerosis [S], interstitial fibrosis/tubular atrophy [T], & crescents [C]), per revised Oxford Classification #Nephpearls https://t.co/4jLrZvGyMK https://t.co/TdPWSKwfgb https://t.co/M80bTDINGI

Oct 10, 2023 · 4 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

13c) This would encompass rigorous #bloodpressure control, optimal inhibition of the #RAS, and lifestyle modification, including weight reduction, exercise, smoking cessation, & dietary sodium restriction. https://t.co/4jLrZvGyMK

Oct 10, 2023 · 3 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

10) So how does #IgAN present? Most commonly, #IgAN is asymptomatic and follows a slowly progressive course with approximately 25%–30% of any cohort developing kidney failure within 20–25 years of presentation https://t.co/4jLrZvGyMK https://t.co/9sLGzgQOu1

Oct 10, 2023 · 3 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

6b) #IgAN is relatively rare in individuals of African descent. It is unclear if these observations are due to differences in pathogenesis and/or the contribution of varying genetic and environmental influences. https://t.co/4jLrZvGyMK

Oct 10, 2023 · 3 likes · 1 share · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

3) IgA #nephropathy (#IgAN) is the most common pattern of primary #glomerular disease worldwide and remains a leading cause of #CKD and #kidneyfailure #ESRD #ESKD See https://t.co/4jLrZvGyMK from @goKDIGO https://t.co/A0qqFwzUeX

Oct 10, 2023 · 9 likes · 1 share · 2,636 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

Abendprogramm für Nieren-Fans während des @dgfn_ev Kongresses #dgfn2023: Nierenbiopsiekonferenz mit Prof. Kerstin Amann (Erlangen) https://t.co/wgsu42ORd0 via @YouTube Partner @oegnephro @com_SFNDT Ab 19:15 und später on demand!

Oct 6, 2023 · 2,330 followers View post →

Nader

@Nader62321135 · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Aug 17, 2023 · 4 shares · 87 followers View post →

Maria Angela Gauci

@mariaangela092 · X

RT @UKKidney: A new UK #Kidney Association commentary is now available on the @goKDIGO 2021 Clinical Practice #Guideline for the Management…

Jun 23, 2023 · 6 shares · 105 followers View post →

Andrew Frankel

@AndrewFrankel1 · X

RT @UKKidney: A new UK #Kidney Association commentary is now available on the @goKDIGO 2021 Clinical Practice #Guideline for the Management…

Jun 23, 2023 · 6 shares · 420 followers View post →

The UK Kidney Association

@UKKidney · X

A new UK #Kidney Association commentary is now available on the @goKDIGO 2021 Clinical Practice #Guideline for the Management of #Glomerular Diseases. Read the commentary now

Jun 23, 2023 · 7 likes · 6 shares · 12,065 followers View post →

Laura Ratcliffe

@lauraratcliffe7 · X

That's bedtime reading sorted!! @NephReena @claremorlidge https://t.co/VA9h06697G https://t.co/erhHNmmBFi

Jun 22, 2023 · 1 like · 883 followers View post →

Maria Angela Gauci

@mariaangela092 · X

Thrilled to see our UKKA commentary on the KDIGO GN guideline published online, where we discuss the issues that are specific for implementation in the UK healthcare setting. Worth a read! Visit https://t.co/aSh1U7gGrf #UKKA #GN

Jun 21, 2023 · 5 likes · 105 followers View post →

@LA93319045 · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 13, 2023 · 11 shares View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 12, 2023 · 4 shares · 783 followers View post →

Dr. Yasir Dar

@Yasirdar085 · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 12, 2023 · 11 shares · 352 followers View post →

Rosina Dal Maso

@MasoRosina · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 57 followers View post →

Johndbaptist!

@brosobio · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 1,022 followers View post →

KDIGO

@goKDIGO · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 37,823 followers View post →

KDIGO

@goKDIGO · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 4 shares · 37,823 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 783 followers View post →

CY Teh

@CheeYongTeh1 · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 8 followers View post →

SABARINATH S MD,DM,PDF(Renal Tx),FASN,FISN

@sabarivenus · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 998 followers View post →

Miguel Guillen 140#

@AnayaGuillen · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 11, 2023 · 11 shares · 423 followers View post →

Sayna Norouzi, MD, FASN

@SaynaNorouzi · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 10, 2023 · 4 shares · 5,887 followers View post →

Karen Céspedes

@KarenCespedes22 · X

RT @edgarvlermamd: Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @go…

Jan 10, 2023 · 11 shares · 747 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @goKDIGO #Nephpearls #NephJC

Jan 10, 2023 · 17 likes · 4 shares · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Management of patients with IgAN who remain at high risk for progression after maximal supportive care ca. 2021 from @goKDIGO #Nephpearls #NephJC

Jan 10, 2023 · 31 likes · 11 shares · 33,495 followers View post →

Florian Custodis

@floriancustodis · X

RT @gunnar_heine: Willkommen zu unserer ersten Nierenbiopsienkonferenz auf Markus at Home mit Prof. Kerstin Amann (Erlangen) Prof. Kirsten…

Oct 29, 2022 · 2 shares · 750 followers View post →

SFNDT

@com_SFNDT · X

RT @gunnar_heine: Willkommen zu unserer ersten Nierenbiopsienkonferenz auf Markus at Home mit Prof. Kerstin Amann (Erlangen) Prof. Kirsten…

Oct 28, 2022 · 2 shares · 2,638 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

Willkommen zu unserer ersten Nierenbiopsienkonferenz auf Markus at Home mit Prof. Kerstin Amann (Erlangen) Prof. Kirsten de Groot und Dr. Martin Brzoska https://t.co/amcWjH7Fpc via @YouTube Partner: @dgfn @oegnephro @com_SFNDT @MarcusSaemann @AntMarlies @AKronbichler @dguerrot

Oct 28, 2022 · 5 likes · 2 shares · 2,330 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

RT @dgfn_ev: Nicht verpassen! Nierenbiopsiekonferenz auf MARKUS @ HOMe mit Prof. Dr. Kerstin Amann. Moderatoren: Prof. Dr. Kirsten de Groot…

Oct 27, 2022 · 2 shares · 2,330 followers View post →

martin l

@lesch_l · X

RT @dgfn_ev: Nicht verpassen! Nierenbiopsiekonferenz auf MARKUS @ HOMe mit Prof. Dr. Kerstin Amann. Moderatoren: Prof. Dr. Kirsten de Groot…

Oct 25, 2022 · 2 shares · 170 followers View post →

Deutsche Gesellschaft für Nephrologie (DGfN) e.V.

@dgfn_ev · X

Nicht verpassen! Nierenbiopsiekonferenz auf MARKUS @ HOMe mit Prof. Dr. Kerstin Amann. Moderatoren: Prof. Dr. Kirsten de Groot (Offenbach), Dr. Martin Brzoska und Prof. Dr. Gunnar Heine (beide Frankfurt am Main). Freitag den 28.10.2022 https://t.co/7cG2V8z6Cz

Oct 25, 2022 · 8 likes · 2 shares · 657 followers View post →

Ahmed

@YehiaAhmed99 · X

RT @edgarvlermamd: FSGS: Proteinuria reduction (Therapeutic goals) #Nephpearls

Sep 25, 2022 · 1 share · 180 followers View post →

Katerina

@kateristoska · X

RT @edgarvlermamd: Classification of FSGS from @goKDIGO #Nephpearls

Sep 21, 2022 · 3 shares · 234 followers View post →

Juan Carlos Obaya

@jcobaya69 · X

RT @edgarvlermamd: Classification of FSGS from @goKDIGO #Nephpearls

Sep 21, 2022 · 3 shares · 856 followers View post →

Nikhilb

@Nikhilb5887 · X

RT @edgarvlermamd: Classification of FSGS from @goKDIGO #Nephpearls

Sep 20, 2022 · 3 shares · 444 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Genetic testing may be beneficial for selected patients with FSGS who should be referred to specialized centers with such expertise

Sep 20, 2022 · 5 likes · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Steroid-resistant Primary FSGS: Treatment #Nephpearls

Sep 20, 2022 · 2 likes · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Primary FSGS: Treatment #Nephpearls

Sep 20, 2022 · 2 likes · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

FSGS Treatment: When should immunosuppression not be used #Nephpearls

Sep 20, 2022 · 4 likes · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

FSGS: Proteinuria reduction (Therapeutic goals) #Nephpearls

Sep 20, 2022 · 4 likes · 1 share · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Evaluation of a patient with FSGS #Nephpearls

Sep 20, 2022 · 4 likes · 33,495 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Classification of FSGS from @goKDIGO #Nephpearls

Sep 20, 2022 · 14 likes · 3 shares · 33,495 followers View post →

Princesarann

@Princesarann1 · X

RT @Elena_Cervants: 2/ Matchup 1⃣: PLA2R

Mar 12, 2022 · 2 shares · 1 followers View post →

Elena Cervantes

@Elena_Cervants · X

2/ Matchup 1⃣: PLA2R

Mar 4, 2022 · 3 likes · 2 shares · 1,678 followers View post →

@CKD_ce

@ckd_ce · X

4) . . . with an Oxford score of M1, E0, S1, T0, C0. See info on Oxford score at https://t.co/4jLrZvGyMK and use the handy calculator at https://t.co/Fx3vrhaAL0. Also see discussion of the score (and earn MORE CE/#CME at https://t.co/VhQW0XMCt4, thanks to @edgarvlermamd)

Mar 1, 2022 · 4 likes · 2,636 followers View post →

soda_troubles,https://med-mastodon.com/@haysam

@set_fortess · X

RT @NephJC: T0g #IPNAJC #NephJC Recent KDIGO 2021 guidelines recommended daily glucocorticosteroids 0.5mg/kg/d for 5-7 days at onset of UR…

Jan 26, 2022 · 3 shares · 2,541 followers View post →

Swapnil Hiremath @hswapnil.medsky.social

@hswapnil · X

RT @NephJC: T0g #IPNAJC #NephJC Recent KDIGO 2021 guidelines recommended daily glucocorticosteroids 0.5mg/kg/d for 5-7 days at onset of UR…

Jan 25, 2022 · 3 shares · 21,704 followers View post →

VICTOR SANNA

@VICTORSANNA · X

RT @NephJC: T0g #IPNAJC #NephJC Recent KDIGO 2021 guidelines recommended daily glucocorticosteroids 0.5mg/kg/d for 5-7 days at onset of UR…

Jan 25, 2022 · 3 shares · 2,591 followers View post →

Nephrology Journal Club

@NephJC · X

T0g #IPNAJC #NephJC Recent KDIGO 2021 guidelines recommended daily glucocorticosteroids 0.5mg/kg/d for 5-7 days at onset of URTI in children with frequently relapsing and steroid-dependent NS taking alternate day prednisolone or off it (1C recommendation) https://t.co/aUzyunhkNp

Jan 25, 2022 · 9 likes · 3 shares · 38,217 followers View post →

Florian Custodis

@floriancustodis · X

RT @gunnar_heine: Ausblick Nephrologie 2022 - @MarcusSaemann, @AntMarlies, @AKronbichler https://t.co/3Oxx99HbAT via @YouTube Vienna Callin…

Jan 14, 2022 · 2 shares · 750 followers View post →

marcus_saemann

@MarcusSaemann · X

RT @gunnar_heine: Ausblick Nephrologie 2022 - @MarcusSaemann, @AntMarlies, @AKronbichler https://t.co/3Oxx99HbAT via @YouTube Vienna Callin…

Jan 14, 2022 · 2 shares · 685 followers View post →

Gunnar Henrik Heine

@gunnar_heine · X

Ausblick Nephrologie 2022 - @MarcusSaemann, @AntMarlies, @AKronbichler https://t.co/3Oxx99HbAT via @YouTube Vienna Calling! Markus @ HOMe welcomes @oegnephro - Preview Nephrology 2022 (in German). Foci: Diabetic Nephrology, ANCA-associated Vasculis, Lupus Nephritis

Jan 14, 2022 · 10 likes · 2 shares · 2,330 followers View post →

AcademicCME

@academiccme · X

RT @ckd_ce: 22) Before we go to specific treatment of FSGS, let us look at “General Management Principles for Patients with Glomerular Dise…

Jan 11, 2022 · 2 shares · 649 followers View post →

Charles Pollack MD

@md_pollack · X

RT @ckd_ce: 22) Before we go to specific treatment of FSGS, let us look at “General Management Principles for Patients with Glomerular Dise…

Jan 11, 2022 · 2 shares · 281 followers View post →

@CKD_ce

@ckd_ce · X

27) For more guidance on treatment of steroid-resistant FSGS, see https://t.co/4jLrZvGyMK for @goKDIGO guidance: https://t.co/N7SZ3u84IG

Jan 11, 2022 · 7 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

25) Per https://t.co/4jLrZvGyMK, initial treatment of primary FSGS--with glucocorticoids-- is shown below. Initial high-dose glucocorticoids should be continued until complete remission is achieved, or as tolerated by patients up to a maximum of 16 weeks, whichever is earlier. https://t.co/dz3CCllZvz

Jan 11, 2022 · 8 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

24) So . . . now on to treatment of #FSGS: see

Jan 11, 2022 · 8 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

22) Before we go to specific treatment of FSGS, let us look at “General Management Principles for Patients with Glomerular Diseases”

Jan 11, 2022 · 9 likes · 2 shares · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

21) Genetic testing may be beneficial for selected patients with #FSGS who should be referred to specialized centers with such expertise

Jan 11, 2022 · 7 likes · 2,636 followers View post →

Shubham Kumar

@einsteinkid_007 · X

RT @ckd_ce: 10) Further clarification in the #FSGS space includes standard definitions for remission, relapse, resistance, & treatment depe…

Jan 11, 2022 · 2 shares · 72 followers View post →

GoggleDocs

@GoggleDocs · X

RT @ckd_ce: 10) Further clarification in the #FSGS space includes standard definitions for remission, relapse, resistance, & treatment depe…

Jan 10, 2022 · 2 shares · 3,647 followers View post →

@CKD_ce

@ckd_ce · X

12) Further, adults with #FSGS who do NOT have nephrotic syndrome should be evaluated for a secondary cause https://t.co/4jLrZvGyMK https://t.co/FfbEJiAcrg

Jan 10, 2022 · 9 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

11) There is standard guidance for differentiating between Primary FSGS vs Secondary FSGS, again based on histopathology of the renal biopsy specimen. The first branch point is the presence or absence of nephrotic syndrome. https://t.co/4jLrZvGyMK https://t.co/PYeUZkZRzd

Jan 10, 2022 · 9 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

10) Further clarification in the #FSGS space includes standard definitions for remission, relapse, resistance, & treatment dependence for FSGS https://t.co/4jLrZvGyMK https://t.co/nmL8211HPM

Jan 10, 2022 · 10 likes · 2 shares · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

9) . . . endorsing instead these types & definitions for FSGS going forward: primary, genetic, secondary, and FSGS--undetermined cause. https://t.co/4jLrZvGyMK https://t.co/n4MSIjtUvL

Jan 10, 2022 · 10 likes · 2,636 followers View post →

@CKD_ce

@ckd_ce · X

4) So let's look at Focal Segmental Glomerulosclerosis (#FSGS) 2012 -> 2021 in the evolving @goKDIGO guidance. https://t.co/4jLrZvGyMK https://t.co/eX1FUA5GeX

Jan 10, 2022 · 7 likes · 2,636 followers View post →

Vivekanand Jha | विवेकानन्द झा

@vjha126 · X

RT @edgarvlermamd: Clinical Practice Guideline for the Management of Glomerular Diseases ca. 2021 from @goKDIGO #NephJC #Nephpearls #Visu…

Jan 5, 2022 · 34 shares · 5,589 followers View post →

Carlos Perez.

@perez_busso · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 15, 2021 · 17 shares · 129 followers View post →

KDIGO

@goKDIGO · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 15, 2021 · 17 shares · 37,823 followers View post →

KDIGO

@goKDIGO · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 6 shares · 37,823 followers View post →

Letaief

@hmidato · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 17 shares · 370 followers View post →

@Mulwelisi · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 6 shares · 81 followers View post →

Franklin Loachamin

@FranLoachamin · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 17 shares · 4,886 followers View post →

Muhammad Tahir

@tauhair · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 17 shares · 242 followers View post →

Nicole Slawny, PhD

@NickySlawny · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 6 shares · 192 followers View post →

cardio-met

@cardiomet_CE · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 17 shares · 4,157 followers View post →

veronica coro

@veronicacoro1 · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 17 shares · 110 followers View post →

Amr Nagy

@amronagyMD · X

RT @edgarvlermamd: Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021 #NephJC

Dec 12, 2021 · 17 shares · 388 followers View post →

Dra. Carolina Romo (Ms. Glomerulosa)

@Carolin48914662 · X

En resumen, además del algoritmo previo, en KDIGO 2021 Clinical practice guideline for the management of glomerular diseases, se describe para manejo de Sx nefrótico lo siguiente: https://t.co/EQzZSfGdDK

Nov 17, 2021 · 2 likes · 772 followers View post →

secuencia de ADN mutante

@Rodrigo87532827 · X

RT @MedClubPage: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021. 100, S1–S276

Nov 1, 2021 · 2 shares · 108 followers View post →

Laura

@Laurita14795 · X

RT @MedInternaHUVN: Es lunes y hay que empezar fuerte Glomérulo y sus diferentes entidades

Nov 1, 2021 · 1 share · 48 followers View post →

Medicina Interna - HUVN

@MedInternaHUVN · X

Es lunes y hay que empezar fuerte Glomérulo y sus diferentes entidades

Nov 1, 2021 · 1 like · 1 share · 695 followers View post →

MedClub

@MedClubPage · X

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021. 100, S1–S276

Oct 31, 2021 · 8 likes · 2 shares · 35,130 followers View post →

Vademon24292

@CarlosA09557330 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 7, 2021 · 46 shares · 520 followers View post →

Saludteca

@Saludteca · X

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases https://t.co/iWsl0YpYtb https://t.co/pweEpM52pp

Oct 7, 2021 · 2,001 followers View post →

Alfredo Ruiz

@Mushalf · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 204 followers View post →

César Corchado

@Kaisar_Cor · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 274 followers View post →

Carlos Fuentes

@carlhfuentes · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 58 followers View post →

Heinert Enmanuel

@Hegc1288 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 263 followers View post →

Katherine ELizabeth

@ke0766019 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 50 followers View post →

nefrologaenapuros

@amm_canet · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 35 followers View post →

Manuel Vazquez V

@ManuelVVidaurre · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 277 followers View post →

Julio Montaluisa J.

@JulioMJ98 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 58 followers View post →

Irving Buitron Nieto.

@Irving_Buitron · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 368 followers View post →

Vero

@vero_r7777 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 87 followers View post →

Vero

@holasoyzuri7 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 6, 2021 · 46 shares · 85 followers View post →

Edgar Soto Vázquez

@Edgar47892407 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 59 followers View post →

mer.

@maarleyruiz · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 127 followers View post →

The BitterDoc

@TheBitterDoc · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 813 followers View post →

Coreas07

@Coreas07 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 132 followers View post →

Laura Alvarez

@pipertaza · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 611 followers View post →

Duncan Ali Montoya

@kodielhuron · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 169 followers View post →

Cristina Toro

@CristinaToro5 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 220 followers View post →

JoséAlbertoLaraMora

@JALM8 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 504 followers View post →

Servei de Farmàcia Parc Taulí

@FarmaciaTauli · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 697 followers View post →

Valentín Gallegos

@valenttin102 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 143 followers View post →

RODRIGO LUNA

@RODRIGO32984659 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 20 followers View post →

Renacido

@elgineco12 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 108 followers View post →

Md. Agatha Reyes Palma

@Ftale94 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 738 followers View post →

Yoiner chavez

@YoinerN · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 60 followers View post →

El Josefo

@_JoseAlfaro · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 241 followers View post →

Ricardo Bedón

@ricardo_bedon · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 1,496 followers View post →

Ivanna Jaramillo

@ivannaje1 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 36 followers View post →

Isa García

@isagarcia_p · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 1,444 followers View post →

Daniel Aparicio

@AparicioDanie12 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 102 followers View post →

Juan.Diego_

@JuanDiegoTR_ · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 137 followers View post →

Dra. Amiodarona

@JessiQuinta25 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 142 followers View post →

Dr. Luis Arturo Carpio, MD.

@Drluiscarpio · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 279 followers View post →

Ilseyih

@Ilseyih · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 748 followers View post →

Henry, come on

@louii_28 · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 1,126 followers View post →

Castañeda R

@TaniaCastanedaR · X

RT @MedClubPage: #Nefrología #KDIGO

Oct 5, 2021 · 46 shares · 137 followers View post →

MedClub

@MedClubPage · X

#Nefrología #KDIGO

Oct 5, 2021 · 132 likes · 46 shares · 35,130 followers View post →

EvidenceStock

@EvidenceStock · X

RT @q0_0_: 9年振りにKDIGOの糸球体腎炎の治療ガイドラインが改定されました。一次性ネフローゼ症候群の治療において、rituximabがどう位置付けられたのかが気になります。 https://t.co/AHqHy5jlwM

Sep 29, 2021 · 1 share · 44 followers View post →

山本陵平

@yamamotoryohei_ · X

9年振りにKDIGOの糸球体腎炎の治療ガイドラインが改定されました。一次性ネフローゼ症候群の治療において、rituximabがどう位置付けられたのかが気になります。 https://t.co/AHqHy5jlwM

Sep 26, 2021 · 1 like · 1 share · 216 followers View post →

Luis Alberto

@lalberth19 · X

RT @Links_Medicus: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. – via @goKDIGO https://t.co/x6P8Vb1Nl…

Sep 21, 2021 · 2 shares · 381 followers View post →

Dr. Euclides Cavalcanti

@Links_Medicus · X

KDIGO 2021 clinical practice guideline for the management of glomerular diseases. – via @goKDIGO https://t.co/x6P8Vb1Nlf Executive summary: https://t.co/XQHojrRbkL

Sep 21, 2021 · 1 like · 2 shares · 29,451 followers View post →

El Residente Chapín

@residentechapin · X

KDIGO se complace en anunciar la publicación de la Guía de práctica clínica 2021 para el manejo de enfermedades glomerulares. La guía ya está disponible en línea y se publicará en la edición de octubre de Supplements to Kidney International. https://t.co/Dg4UoVKfHZ https://t.co/kSZtt7tIBt

Sep 21, 2021 · 109 followers View post →

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions